We discuss the advantages of using X-ray crystallography and cryo-EM in 3D epitope mapping. We show that these methods can reveal conformational dynamics and allosteric effects within the antibody-antigen complex.
We highlight a study conducted by the AstraZeneca team on synchrotron X-ray crystallography in drug discovery (Käck & Sjögren, 2024).
Technical developments have made crystallographic fragment screening the most effective method for screening fragment libraries. Here, we provide a brief overview of the method and its requirements.
Macrocyclic peptide drug structures (often 4 to 24 amino acids) fall between small-molecule drugs and biologics (such as monoclonal antibodies). We discuss the unique features of these structures.
We discuss the the early drug discovery services market and highlight the integrated drug discovery CRO services provided by SARomics Biostructures.
It was a year marked by the most significant changes in recent memory: a new home for the company, four new team members, new collaborations, new publications, a revamped homepage, and a greatly expanded list of off-the-shelf structures.
SARomics Biostructures AB and Vipergen ApS partner to offer hit and lead identification services based on Vipergen’s unique DNA-encoded library (DEL) screening technology.
In the this article we discuss evidence that shows that NMR spectroscopy is far superior to other established methods for biosimilar’s higher order structure analysis.
In this article, we discuss weak affinity chromatography (WAC™), the proprietary fragment screening technique jointly owned by SARomics Biostructures and Red Glead Discovery.
In this article, we will discuss some significant publications and company activities in 2023. The publications showcase our expertise in the three main areas of our services: X-ray crystallography, NMR spectroscopy, and integrated drug discovery.